-

The Honorable David Shulkin, M.D. Joins Orpyx Advisory Board to Advance Veteran Care and Diabetes Prevention Market Growth

CALGARY, Alberta--(BUSINESS WIRE)--Today, Orpyx® Medical Technologies Inc. (Orpyx) announced the addition of Dr. David Shulkin, the Ninth Secretary of the U.S. Department of Veterans Affairs (VA), to its advisory board. Secretary Shulkin brings unmatched expertise in policy, operations, and innovation adoption within the VA and across U.S. healthcare systems.

“Preventing diabetic foot ulcers and amputations is not only a critical medical priority but also a major economic imperative.” — The Honorable David Shulkin, M.D.

Share

The Department of Veterans Affairs (VA) is one of the largest integrated health systems in the world, uniquely positioned to improve the lives of Veterans with its multidisciplinary Prevention of Amputations In Veterans Everywhere (PAVE) program. According to Veteran Health Administration (VHA) data, there are over 1.6 million Veterans with diabetes receiving care within the VHA. In fiscal year 2024, VHA treated over 49,000 diabetic foot ulcers (DFUs). Of those who develop an ulcer, 15% will require amputation. Preventive measures are crucial and can save VHA roughly $50,000 in direct medical costs per prevented amputation.

“Preventing diabetic foot ulcers and amputations is not only a critical medical priority but also a major economic imperative,” said Secretary David Shulkin. “Orpyx’s technology directly supports the VA’s mission to improve Veteran health outcomes, advance value-based care, and reduce the substantial costs associated with diabetes-related complications.”

“Secretary Shulkin is a nationally recognized healthcare policy leader at the forefront of value-based care and chronic disease prevention,” said Breanne Everett, CEO and founder of Orpyx. “His strategic insights will help us rapidly scale across the VA and other major payer networks, advancing our shared mission to reduce diabetes-related foot complications — a challenge that drives more than $80 billion in annual healthcare spending. Together, we can change that trajectory.”

Dr. Shulkin’s appointment underscores Orpyx’s leadership in digital health and strengthens its ability to scale preventive care solutions nationwide.

About Orpyx Medical Technologies Inc.

Orpyx® is a health technology company helping people with diabetes stay on their feet and preserve independence through its patented sensor-enabled smart insole system and integrated remote care program. Built to detect early warning signs and prompt timely intervention, the Orpyx solution helps improve adherence, reduce total costs, and preserve mobility and quality of life. The company partners with VA Medical Centers, health systems, and payers across North America to deliver clinically validated outcomes and cost savings at scale.

Contacts

Media Inquiries:

Karen Smith
SVP, Marketing & Strategic Market Access
karen.smith@orpyx.com
210-823-9604
www.orpyx.com

Orpyx Medical Technologies Inc.


Release Versions

Contacts

Media Inquiries:

Karen Smith
SVP, Marketing & Strategic Market Access
karen.smith@orpyx.com
210-823-9604
www.orpyx.com

More News From Orpyx Medical Technologies Inc.

Orpyx Medical Technologies Supplies Digital Health Platform for NIH-Funded and Johns Hopkins Medicine–Led Clinical Trial on Diabetic Foot Ulcer Prevention

CALGARY, Alberta--(BUSINESS WIRE)--Orpyx® Medical Technologies announced today that its sensory insoles, analytics platform, and remote monitoring program will be used in a new clinical trial funded by the National Institutes of Health (NIH). The WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention study will be led by Johns Hopkins University School of Medicine, with collaborators from Keck Medicine of USC and the University of Utah Spencer Fox Eccles School of Medicine. The $5 mi...

Orpyx Launches Sensory Insole Program to Combat >$80B Annual Cost of Diabetic Foot Complications

CALGARY, Alberta--(BUSINESS WIRE)--Orpyx launches next-gen sensory insole program to prevent diabetic foot ulcers, reduce costs, and support value-based care through remote monitoring....

Orpyx Secures $20M Investment Led by Perceptive Advisors

NEW YORK & CALGARY, Alberta--(BUSINESS WIRE)--Orpyx Medical Technologies Inc. (Orpyx®), the leader in diabetic foot ulcer (DFU) and amputation prevention, announced the completion of an additional $20 million in growth capital led by Perceptive Advisors (Perceptive). “Orpyx is an innovator in diabetic foot ulcer prevention,” said Sam Chawla, Portfolio Manager at Perceptive Advisors. “We are excited to partner with the company to support the mission of improving the lives of people at risk from...
Back to Newsroom